RGNCY-0012 (CD532)

SOLD OUT!!  E-mail us at info@reagency.co if you are interested in this product.

MYCN is an important driver of some cancers however, due to a lack of small molecule binding surfaces it has not been considered drugable. CD532 disrupts the normal confirmation of Aurora A (IC50 = 48nM), driving the degradation of MYCN protein in MYCN-driven cancers. This degradation has been shown to be cytotoxic in MYCN-amplified neuroblastoma cells and has been demonstrated as effective in vivo.

Systematic Name: 1-(4-((4-((5-cyclopentyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)amino)phenyl)-3-(3-(trifluoromethyl)phenyl)urea


Molecular Weight:

Formula: C26H25F3N8O

PMID: 25175806

Reference: Gustafson, William Clay, et al. "Drugging MYCN through an Allosteric Transition in Aurora Kinase A." Cancer Cell 26.3 (2014): 414-427.

Interested in this reagent? E-mail us at info@reagency.co and let us know.

Tags: MYCN, Cancer, RGNCY-0012, CD532, Aurora A, Neuroblastoma